Literature DB >> 17959406

CLN2/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype.

C Bessa1, C A Teixeira, A Dias, M Alves, S Rocha, L Lacerda, L Loureiro, A Guimarães, M G Ribeiro.   

Abstract

The classical form of late infantile neuronal ceroid lipofuscinosis (LINCL) is a childhood hereditary neurodegenerative disease usually fatal in the first decade of life. The underlying gene, CLN2, encodes the lysosomal soluble enzyme tripeptidyl-peptidase 1 (TPP1). In a Portuguese patient with juvenile form of the disease, the histochemical study revealed the presence of curvilinear inclusions typical of LINCL. In vitro TPP1 activity was deficient in patient's cells. CLN2 gene analysis revealed the transition IVS7-10A>G (g.4196A>G) in both alleles. In silico analysis suggested that A-to-G change in the A-rich region of intron 7 could cause aberrant splicing of exon 8 by creating a novel acceptor splice site. However, because the wild-type acceptor of intron 7 is weak and it was not apparently affected, the severity of this mutation could not be established through sequencing data of gDNA. Normal level of spliced CLN2/mRNA was observed in patient's fibroblasts. In the cDNA, the 9-nt retention of intronic sequence (c.886_887ins9) was observed. The mutation is predicted to result in a protein with three extra amino acids between proline 295 and glycine 296. In patient's fibroblasts the level of mutant CLN2p was reduced to about 60% but the migration pattern was similar to the wild-type protein, suggesting that it was correctly targeted to the lysosomes. Taken together, these findings suggest that the first "ag" is selected for splicing and the mutant protein must retain some residual catalytic activity, thus explaining the late onset and the delayed progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959406     DOI: 10.1016/j.ymgme.2007.08.124

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.

Authors:  Feng Yu; Xiao-Min Liu; Yin-He Chen; Sheng-Quan Zhang; Kai Wang
Journal:  Neurol Sci       Date:  2015-06-02       Impact factor: 3.307

Review 2.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

3.  Visual perception and macular integrity in non-classical CLN2 disease.

Authors:  Angela Schulz; Simon Dulz; Yevgeniya Atiskova; Jan Wildner; Eva Wibbeler; Miriam Nickel; Martin Stephan Spitzer; Christoph Schwering
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-02       Impact factor: 3.535

4.  A novel mutation in the MFSD8 gene in late infantile neuronal ceroid lipofuscinosis.

Authors:  E Stogmann; S El Tawil; J Wagenstaller; A Gaber; S Edris; A Abdelhady; E Assem-Hilger; F Leutmezer; S Bonelli; C Baumgartner; F Zimprich; T M Strom; A Zimprich
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

5.  Early-onset Lafora body disease.

Authors:  Julie Turnbull; Jean-Marie Girard; Hannes Lohi; Elayne M Chan; Peixiang Wang; Erica Tiberia; Salah Omer; Mushtaq Ahmed; Christopher Bennett; Aruna Chakrabarty; Atul Tyagi; Yan Liu; Nela Pencea; XiaoChu Zhao; Stephen W Scherer; Cameron A Ackerley; Berge A Minassian
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

6.  Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.

Authors:  Romina Kohan; María Noelia Carabelos; Winnie Xin; Katherine Sims; Norberto Guelbert; Inés Adriana Cismondi; Patricia Pons; Graciela Irene Alonso; Mónica Troncoso; Scarlet Witting; David A Pearce; Raquel Dodelson de Kremer; Ana María Oller-Ramírez; Inés Noher de Halac
Journal:  Gene       Date:  2012-12-22       Impact factor: 3.688

7.  "Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series".

Authors:  O M Espitia Segura; Z Hernández; N I Mancilla; R A Naranjo; L Tavera
Journal:  Mol Genet Metab Rep       Date:  2021-02-03

8.  Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world.

Authors:  Charles M Lourenço; Andre Pessoa; Carmen C Mendes; Carolina Rivera-Nieto; Diane Vergara; Mónica Troncoso; Emily Gardner; Francisca Mallorens; Lina Tavera; Luis A Lizcano; Nora Atanacio; Norberto Guelbert; Norma Specola; Nury Mancilla; Carolina F M de Souza; Sara E Mole
Journal:  J Paediatr Child Health       Date:  2020-12-30       Impact factor: 1.954

9.  Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.

Authors:  Eva Wibbeler; Raymond Wang; Emily de Los Reyes; Nicola Specchio; Paul Gissen; Norberto Guelbert; Miriam Nickel; Christoph Schwering; Lenora Lehwald; Marina Trivisano; Laura Lee; Gianni Amato; Jessica Cohen-Pfeffer; Renée Shediac; Fernanda Leal-Pardinas; Angela Schulz
Journal:  J Child Neurol       Date:  2020-12-23       Impact factor: 1.987

Review 10.  Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.

Authors:  Miriam Nickel; Angela Schulz
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.